Stockscreener 앱 받기
13.56
1.65%
0.22
시장 영업 전:
13.56
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News
Bicycle therapeutics executive sells shares worth over $21k - Investing.com India
Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India
Bicycle therapeutics COO sells shares worth over $21k - Investing.com India
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bicycle therapeutics CTO sells shares worth over $21k - Investing.com
Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com
CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguso sale 246 shares of Bicycle Therapeutics Plc ADR [BCYC] – Knox Daily - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock chart: A technical perspective - US Post News
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 22.56 - The Dwinnex
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com
A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily
Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News
RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily
Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex
Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News
Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily
Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK
4.81%
자본화:
|
볼륨(24시간):